Evidence map›Paper›PMID 38374215›Full record

ArticleSkeletal radiology2024

Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.

Wetterwald Laureline, Omoumi Patrick, Nguyen Tu, Cherix Stephane, Dolcan Ana, Ferraro Daniela, Saglietti Chiara, Letovanec Igor, Digklia Antonia

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Skeletal radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wetterwald LaurelineDepartment of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Omoumi PatrickDepartment of Diagnostic Radiology And Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Nguyen TuDepartment of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Cherix StephaneDepartment of Orthopaedics and Traumatology, Lausanne University Hospital, Lausanne, Switzerland.
Dolcan AnaDepartment of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Ferraro DanielaDepartment of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Saglietti ChiaraInstitute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Letovanec IgorInstitute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Digklia AntoniaDepartment of Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. antonia.digklia@chuv.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign fibrous histiocytoma of the bone (BFHB) is a rare mesenchymal tumor, representing less than 1% of all benign bone tumors. This controversial entity is characterized by a mixture of fibroblasts arranged in a storiform pattern, varying amounts of osteoclast-type giant cells and foamy macrophages. Curettage or simple resection is usually curative. However, it was reported that up to 11% of the patients suffer from relapse. Here, we report a case of malignant transformation of BFHB after long-lasting disease stabilization under denosumab therapy.

Indexed as

Bone Density Conservation AgentsBone NeoplasmsDenosumabHistiocytoma, Benign FibrousNeoplasm Recurrence, LocalCell Transformation, NeoplasticFemaleHumansMagnetic Resonance ImagingMaleTomography, X-Ray ComputedBone Density Conservation AgentsDenosumabBenign fibrous histiocytoma of bone (BFHB)CancerDenosumabPelvic boneTransformation

Identifiers

PMID38374215
PMCPMC11410898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.